Active ingredient: Glyburide
Form/Route: Tablet; Oral
Recommended studies: 2 Studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 5 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional Comments: To avoid hypoglycemic episodes in healthy volunteers, the drug products should be administered with 240 mL of 20% glucose solution in water. After dosing, 60 mL of 20% glucose solution should be given to each subject every 15 minutes for the following 4 hours.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 5 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional Comments: See comments above. Please refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Glyburide in plasma

Bioequivalence based on (90% CI): Glyburide

Waiver request of in-vivo testing: 1.25 mg and 2.5 mg based on (i) acceptable bioequivalence studies on the 5 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths. Please refer to the Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in-vivo testing.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each for all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Mar 2012